Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes.
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
accepted:
22
07
2019
pubmed:
25
7
2019
medline:
3
3
2021
entrez:
24
7
2019
Statut:
ppublish
Résumé
To assess the relevance of lipoprotein-associated phospholipase A2 activity as a diagnostic and prognostic marker for renal microvascular diseases. We analysed lipoprotein-associated phospholipase A2 activity and lysophosphatidylcholine levels (as a surrogate marker of oxidative stress) in 165 adolescents (aged 17.0 ± 2.3 years) with a history of Type 1 diabetes greater than 10 years. Clinical data were obtained from the German/Austrian nationwide Diabetes-Patients Follow-up (DPV) registry at blood collection and on average 2.4 ± 1.3 years later at follow-up. Relationships between lipoprotein-associated phospholipase A2 activity and clinical, demographic and laboratory variables, lysophosphatidylcholine levels and presence of albuminuria were evaluated by multivariable linear and logistic regression. Lipoprotein-associated phospholipase A2 activity was higher in male than female adolescents (P = 0.002). Albuminuria was present in 14% (22/158) of participants at baseline, and 5% (4/86) of participants without albuminuria at baseline developed albuminuria until follow-up. Lipoprotein-associated phospholipase A2 activity was associated neither with present nor with incident albuminuria. Lysophosphatidylcholine did not correlate with lipoprotein-associated phospholipase A2 activity. Cross-sectional bivariate correlation as well as multivariable linear regression analysis revealed a negative correlation of lipoprotein-associated phospholipase A2 activity with HbA Lipoprotein-associated phospholipase activity was not associated with surrogate markers for oxidative stress and early diabetic nephropathy. The association of decreased lipoprotein-associated phospholipase A2 activity with poor glucose control might limit its function as a predictor of micro- and macrovascular diseases in Type 1 diabetes.
Substances chimiques
Biomarkers
0
Lysophosphatidylcholines
0
1-Alkyl-2-acetylglycerophosphocholine Esterase
EC 3.1.1.47
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-83Informations de copyright
© 2019 Diabetes UK.
Références
The Lp-PLA2 Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-1544.
Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 2001; 1: 121-125.
Siddiqui MK, Kennedy G, Carr F, Doney ASF, Pearson ER, Morris AD et al. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia 2018; 61: 1344-1353.
Canning P, Kenny BA, Prise V, Glenn J, Sarker MH, Hudson N et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. Proc Natl Acad Sci U S A 2016; 113: 7213-7218.
Pearce I, Simo R, Lovestam-Adrian M, Wong DT, Evans M. Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. Diabetes Obes Metab 2019; 21: 467-478.
Hagg S, Thorn LM, Putaala J, Liebkind R, Harjutsalo V, Forsblom CM et al. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care 2013; 36: 4140-4146.
Huang Y, Wu Y, Yang Y, Li W, Lu J, Hu Y. Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China. Sci Rep 2017; 7: 16092.
Muller J, Petkovic M, Schiller J, Arnold K, Reichl S, Arnhold J. Effects of lysophospholipids on the generation of reactive oxygen species by fMLP- and PMA-stimulated human neutrophils. Luminescence 2002; 17: 141-149.
Jha JC, Ho F, Dan C, Jandeleit-Dahm K. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci (Lond) 2018; 132: 1811-1836.
Fortunato J, Blaha V, Bis J, St'asek J, Andrys C, Vojacek J et al. Lipoprotein-associated phospholipase A(2) mass level is increased in elderly subjects with type 2 diabetes mellitus. J Diabetes Res 2014; 2014: 278063.
Charniot JC, Khani-Bittar R, Albertini JP, Giral P, Cherfils C, Cosson C et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol 2013; 168: 132-138.
Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 2010; 59: 1239-1243.
Nelson TL, Kamineni A, Psaty B, Cushman M, Jenny NS, Hokanson J et al. Lipoprotein-associated phospholipase A(2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. Diabetologia 2011; 54: 329-333.
Sanchez-Quesada JL, Vinagre I, de Juan-Franco E, Sanchez-Hernandez J, Blanco-Vaca F, Ordonez-Llanos J et al. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol 2012; 110: 67-71.
Mayer O, Jr, Seidlerova J, Filipovsky J, Timoracka K, Bruthans J, Vanek J et al. Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease. Eur J Intern Med 2014; 25: 556-560.
de Castro SH, Faria Neto HC, Gomes MB. Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus. Arq Bras Cardiol 2007; 88: 179-184.
Gomes MB, Cobas RA, Nunes E, Nery M, Castro-Faria-Neto HC, Tibirica E. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes. Prostaglandins Other Lipid Mediat 2008; 87: 42-46.
Seyfarth J, Reinehr T, Hoyer A, Reinauer C, Bachle C, Karges B et al. Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes. J Inherit Metab Dis 2018; 41: 73-79.
Stahl A, Strassburger K, Lange K, Bachle C, Holl RW, Giani G et al. Health-related quality of life among German youths with early-onset and long-duration type 1 diabetes. Diabetes Care 2012; 35: 1736-1742.
Reinauer C, Rosenbauer J, Bachle C, Herder C, Roden M, Ellard S et al. The clinical course of patients with preschool manifestation of Type 1 diabetes Is independent of the HLA DR-DQ genotype. Genes (Basel) 2017; 8: pii: E146.
Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with Type 1 diabetes. JAMA 2017; 318: 1358-1366.
Deutsche Diabetes Gesellschaft. S3-Leitlinie der DDG und AGPD, Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. 2015. Available at http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/DM_im_Kinder-_und_Jugendalter_20151206.pdf
Donaghue KC, Marcovecchio ML, Wadwa RP, Chew EY, Wong TY, Calliari LE et al. ISPAD Clinical Practice Consensus Guidelines 2018: microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes 2018; 19(Suppl 27): 262-274.
Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 1992; 11: 1305-1319.
Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy: a review. Int J Nephrol Renovasc Dis 2017; 10: 221-231.
Kim M, Jung S, Kim SY, Lee SH, Lee JH. Prehypertension-associated elevation in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidative stress. PLoS One 2014; 9: e96735.
Gao S, Zhao D, Wang M, Zhao F, Han X, Qi Y et al. Association between circulating oxidized LDL and atherosclerotic cardiovascular disease: a meta-analysis of observational studies. Can J Cardiol 2017; 33: 1624-1632.
Silva IT, Mello AP, Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)): a review. Lipids Health Dis 2011; 10: 170.
Kujiraoka T, Iwasaki T, Ishihara M, Ito M, Nagano M, Kawaguchi A et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 2003; 44: 2006-2014.
Memon RA, Saeed SA, Jabbar A, Jafri A, Gilani AH, Saleem S et al. Altered platelet activating factor metabolism in insulin dependent diabetes mellitus. J Pak Med Assoc 1995; 45: 122-125.